Stage (next event)
Catalyst Info & Data Links
TITLE: Selinexor (XPOVIO) in Liposarcoma | SEAL - NDA Submission
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2018: Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
Mechanism of Action
MECHANISM OF ACTION/RATIONALE
Nuclear export inhibitor
Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways
1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post